Altius Direct Electrical Nerve Stimulation System
Neuros Medical, Inc. · Decision date May 5, 2026
What did the FDA approve?
FDA records P230020/S006 as a supplement to PMA P230020, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated May 5, 2026.
FDA approval order statement
approval for the addition of an alternate test method (Bacterial Endotoxin Testing Chromogenic) for endotoxin testing of the Implantable Pulse Generator (IPG) and IPG Accessory Kit components of the Altius System and a change in the test lab supplier for endotoxin testing from Integer Uruguay to Labcorp and Integer Plymouth.
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- May 5, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230020/S006
- Regulatory pathway
- PMA supplement
- Applicant
- Neuros Medical, Inc.
- Product code
- SAZ
- Decision code
- APPR
- Decision date
- May 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: stimulator, nerve terminus, totally implanted for chronic intractable post-amputation pain of the lower limb.
- Applicant
- Neuros Medical, Inc.
- Product code
- SAZ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230020. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230020 · Original PMA
Altius Direct Electrical Nerve Stimulation System
P230020/S006 received
Application receipt date recorded by FDA.
P230020/S005 · Related supplement
Altius Direct Electrical Nerve Stimulation System
P230020/S007 · Related supplement
Altius Direct Electrical Nerve Stimulation System
P230020/S006 · FDA decision
135 Review Track For 30-Day Notice
P230020/S011 · Related supplement
Altius Direct Electrical Nerve Stimulation System
Timeline entries are records held by MedtechLedger for P230020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Neuros Medical, Inc. | PMA approval | Aug 26, 2024 | FDA | |
| Neuros Medical, Inc. | PMA supplement | Dec 3, 2025 | FDA | |
| Neuros Medical, Inc. | PMA supplement | Feb 28, 2026 | FDA | |
| Neuros Medical, Inc. | PMA supplement | Oct 16, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Neuros Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 26800 Aliso Viejo Pkwy., Suite 250, Aliso Viejo, CA, 92656
Sources and methodology
- Original FDA record: P230020/S006
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


